19208-Lung Cancer-NA-458

Lung Cancer

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number:

  • Address

4708 Alliance Blvd, Suite 150
Plano, TX 75093
P: (972) 596-7801

Search by practice name, trial titles, indicators and specific disease types.